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Abstract
Adeno-associated- (AAV) based vectors are promising tools for gene therapy applications in several organs, including the brain, but are
limited by their small genome size. Two short promoters, the human synapsin 1 gene promoter (hSYN) and the murine cytomegalovirus
immediate early promoter (mCMV), were evaluated in bicistronic AAV-2 vectors for their expression profiles in cultured primary brain cells
and in the rat brain. Whereas transgene expression from the hSYN promoter was exclusively neuronal, the murine CMV promoter targeted
expression mainly to astrocytes in vitro and showed weak transgene expression in vivo in retinal and cortical neurons, but strong expression
in thalamic neurons. We propose that neuron specific transgene expression in combination with enhanced transgene capacity will further
substantially improve AAV based vector technology.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
Gene therapy vectors based on recombinant adeno-asso-
ciated virus (AAV; Parvoviridae, Parvovirinae, Dependovi-
rus) have become widely accepted for transduction of the
brain. They show neither inherent vector toxicity nor im-
munogenicity and are not associated with any known human
disease. Long-lasting transgene expression from the recom-
binant genome, which is devoid of all viral genes except the
short inverted terminal repeats (ITRs), is a further benefit
(Peel and Klein, 2000). Recently developed improvements
for production of recombinant vectors (Grimm et al., 1998;
Zolothukin et al., 1999) may soon allow for clinical trials
using AAV based vectors for the treatment of challenging
diseases such as Parkinson’s syndrome (Bjorklund et al.,
2000). The main issue of AAV based vectors is the rela-
tively small genome size which must not substantially ex-
ceed 5000 bp, including 300 bp for the ITRs (Dong et al.,
1996). In order to retain sufficient capacity for one or more
transgenes (e.g., a therapeutic and a reporter gene) tran-
scriptional control elements should be as small as possible.
This can be achieved by the use of ubiquitously active viral
promoters such as the human cytomegalovirus (hCMV) or
the SV-40 promoter. However, forthcoming gene therapy
applications will require cellular promoters restricting trans-
gene expression to defined tissues as an important safety
criterion. So far, cellular promoters used to drive efficient
transgene expression in the brain from AAV vectors were
relatively bulky promoters like the neuron specific enolase
(NSE) promoter (1800 bp), the hybrid CMV/chicken -ac-
tin (CBA) promoter (1700 bp), or the platelet-derived
growth factor- chain promoter (1500 bp) (Paterna et al.,
2000; Bjo¨rklund et al., 2000; Xu et al., 2001).
The small human synapsin 1 gene promoter (hSYN, 480
bp) has recently been shown to target transgene expression
from adenoviral vectors exclusively to neurons in vitro and
in vivo, although the tropism of adenoviral vectors favour
glial transduction (Ku¨gler et al., 2001; Glover et al., 2002).
Furthermore, this promoter showed long-term transgene ex-
pression from an adenoviral vector in the rat brain in vivo
(Ku¨gler et al., 2002). Since the hSYN promoter is only 480
bp in length we supposed that it would be ideally suited to
drive transgene expression from AAV vectors in the brain.
As another small promoter that has not been tested in
AAV vectors before, we investigated the murine cytomeg-
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alovirus (mCMV) immediate early promoter (527 bp). The
mCMV immediate early promoter has been demonstrated to
be extremely powerful when used in adenoviral vectors
(Addison et al., 1997; Gerdes et al., 2000). We therefore
aimed to evaluate the expression characteristics of this pro-
moter in an AAV-2 vector, because this virus has been
reported to have a neuron restricted tropism (Bartlett et al.,
1998). We intended to determine whether the ubiquitously
active mCMV promoter, which after adenoviral transduc-
tion of the brain is highly active in glial cells, may be
“retargeted” to neurons by a vector with preferential neu-
ronal tropism.
By using bicistronic AAV-2 vectors expressing two
transgenes (a “functional” transgene plus a reporter gene)
contemporaneously from either the hSYN or the mCMV
promoter, we demonstrate that (1) the hSYN promoter con-
ferred exclusive neuronal expression in vitro and in vivo;
(2) the murine CMV promoter showed diverse expression
profiles in the brain, with high activity in thalamic neurons
but very weak activity in cortical and retinal neurons; (3)
unlike in the adult rat brain, AAV-2 vectors efficiently
transduced glial cells in vitro if the transgene is under
control of the mCMV promoter; and (4) small transcrip-
tional control units allow for the efficient expression of two
transgenes from AAV-2 vectors under control of a cellular
promoter.
Results
Two bicistronic recombinant AAV-2 vectors were con-
structed: AAV-6p1 expressed Bcl-XL (tagged with the
FLAG epitope) under control of the human synapsin 1 gene
(hSYN) promoter and, in a separate expression cassette,
EGFP likewise from the hSYN promoter. AAV-8a2 ex-
pressed Bcl-XL from the hSYN promoter but expressed
EGFP under control of the murine cytomegalovirus
(mCMV) promoter. The Bcl-XL expression cassette con-
tained a small chimeric intron and the SV-40 polyadenyla-
tion site, whereas the EGFP expression cassette contained
the woodchuck hepatitis virus posttranslational control ele-
ment (WPRE) and the bGH polyadenylation site (Fig. 1a).
In order to evaluate the general expression characteristics of
the hSYN and the mCMV promoters, cultures of primary
hippocampal neurons and glial cells were transduced and
EGFP expression was monitored over time in situ (Fig.
1b–n). We found that the mCMV promoter mediated stron-
ger EGFP expression during the first 3–5 days after trans-
duction (Fig. 1b–j) but the hSYN promoter caught up at
about 5–7 days after transduction (Fig. 1h–n). Strikingly,
mCMV- and hSYN-driven EGFP expression obviously took
place in different cell types, the former expressing mainly in
cells with glial morphology and the latter being clearly
restricted to neurons. To clarify this issue, transduced cul-
tures were stained with antibodies for either the neuron
specific antigen NeuN or the astrocyte specific antigen
GFAP. Although hSYN-driven EGFP expression virtually
exclusively colocalized to NeuN immunoreactivity (Fig.
2a–c), we found that mCMV-driven EGFP expression co-
localized to NeuN immunoreactivity only in a few cells
(Fig. 2d–f) but instead showed colocalization with the as-
trocyte marker GFAP (Fig. 2g–i).
We also investigated whether both the Bcl-XL and the
EGFP transgenes were properly expressed from both vec-
tors. Since cultured hippocampal neurons endogenously ex-
pressed substantial amounts of Bcl-XL (not shown) we used
the FLAG epitope tag to detect Bcl-XL expressed from the
viral vectors in vitro. After AAV-6p1 transduction, FLAG
immunoreactivity was detected in most neurons that also
expressed EGFP, although the total number of FLAG-pos-
itive cells was reduced by about 25% as compared with the
number of EGFP-expressing cells (Fig. 2k–m). After AAV-
8a2 transduction, EGFP expression mainly took place in
cells that showed no FLAG immunoreactivity, indicating
that with this vector mCMV driven EGFP expression
mainly occurred in glial cells (astrocytes) whereas hSYN
driven Bcl-XL expression occurred in neurons (Fig. 2n–p).
The unexpected expression properties of the mCMV
promoter were further investigated in vivo by transduction
of the adult rat retina and brain. In the intraocularly trans-
duced retina we found that EGFP expression from the
hSYN promoter was highly retinal ganglion cell specific, as
demonstrated by colocalization with the retrograde tracer
FluoroGold (Fig. 3a–c). Only few cells of the inner nuclear
layer were also transduced. By immunofluorescent staining
with an Bcl-X antibody we found virtually complete colo-
calization of EGFP fluorescence and Bcl-XL expression in
retinal ganglion cells after transduction with AAV-6p1 (Fig.
3d). Bcl-XL expression was also detected specifically in
retinal ganglion cells (RGCs) after transduction with AAV-
8a2, which expressed this transgene from the hSYN pro-
moter; however, EGFP expression driven by the mCMV
promoter was barely detectable in RGCs, whereas some
Muller glia cells showed pronounced EGFP fluorescence
(Fig. 3e and f).
After vector injection into the brain parenchyma, EGFP
expression was completely restricted to neurons when
driven by the hSYN promoter as revealed by colocalization
with the neuron specific antigen, NeuN (Fig. 3g–j). The
mCMV promoter, however, showed diverse expression
characteristics: in the motorcortex strong EGFP expression
was detected in a small number of astrocytes (as identified
with GFAP immunostaining, not shown), whereas expres-
sion in neurons was very weak (Fig. 3k and l). In contrast,
after transduction of the thalamus equal levels of EGFP
expression were detected from both the mCMV and the
hSYN promoters (Fig. 3m and n).
When we compared the number of cells expressing either
EGFP or Bcl-XL after AAV-6p1 transduction in the stria-
tum, we found that in accordance with the results obtained
in vitro, about 30  4% of EGFP-expressing cells did not
express Bcl-XL. These results indicated that the Bcl-XL
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expression cassette, which contained the small intron and
SV40 polyadenylation site, is somewhat less effective than
the EGFP expression cassette that contained the WPRE and
bGH polyadenylation site (Fig. 3o–r).
Discussion
AAV-based vectors are rapidly emerging tools for gene
therapy applications and many significant improvements
regarding vector production, purification, and enhanced
transgene expression have been accomplished. Downsizing
transcriptional control elements allows for enhanced trans-
gene capacities, and the use of cellular promoters, which
show highly cell-type-restricted activity, adds an important
safety feature to the vector. Here we demonstrated for the
first time that the small human synapsin 1 gene promoter is
suited for gene transfer applications in the brain using AAV
vectors. As well as in adenoviral vectors, the hSYN pro-
moter mediated completely neuron-restricted transgene ex-
pression in both the adult brain and cultured embryonic
neurons. Because vectors based on the AAV-2 capsid show
a high degree of neuronal tropism, the main advantage of
using the hSYN promoter in this type of vector is the gain
in transgene capacity (Fig. 1o). We were able to express
both a putative “functional” transgene (Bcl-XL) and the
fluorescent reporter EGFP independently under control of
cellular promoters. This strategy is promising, especially for
retinal transduction since transgene expression can be mon-
itored in the living animal by fluorescent imaging (Rabi-
nowitz et al., 2002). As retinal ganglion cells are the target
in a well-established axonal lesion model (Ku¨gler et al.,
1999; Kermer et al., 2001), the specific transduction of this
cell type by AAV-2 vectors further strengthened the usabil-
ity of this vector for neurotraumatic research. The vector
system described in this study combines small but abso-
lutely neuron-specific transcription control elements with
highly retinal ganglion cell-specific transduction. It will
allow for the long-term expression of various putatively
neuroprotective proteins in retinal ganglion cells in the
axotomy model of neurotrauma in order to determine the
most effective strategy to overcome neuronal degeneration
after traumatic central nervous system injuries. Notably, the
choice of an appropriate promoter is crucial to the success
of such experiments, as determined by the unexpected fail-
ure of the murine CMV immediate-early promoter to me-
diate transgene expression in retinal ganglion cells irrespec-
tive of the efficient infection of these neurons by the AAV-2
virus particle. If possible, expression cassettes should con-
tain the WPRE element, as we have found both in vitro and
in vivo that about 30% more cells show transgene expres-
sion if this element rather than the chimeric intron was
present. However, this difference was much less dramatic
than that reported by others (Paterna et al., 2000), indicating
that the much smaller intron/SV-40 polyadenylation site
mediated efficient transgene expression as well.
Fig. 1. Expression kinetics of the hSYN and mCMV promoters in cultured
primary brain cells in vitro. (a) The recombinant genomes of the two bicistronic
AAV-2 vectors. Abbreviations: TR, inverted terminal repeats; hSYN1, human
synapsin 1 gene promoter; Bcl-XL, cDNA sequence coding for the rat Bcl-XL
protein; Int, chimeric intron (from the pCI-Neo vector, Promega); SV-40, simian
virus-40-derived polyadenylation site; TB, synthetic transcription blocker; mCMV,
murine cytomegalovirus promoter; EGFP, cDNA coding for enhanced green
fluorescent protein; WPRE, woodchuck hepatitis virus posttranscriptional control
element; bGH, bovine growth hormone gene derived polyadenylation site. Eval-
uation of the basic expression kinetics from the hSYN and mCMV promoters,
respectively, was performed by transduction of primary hippocampal cultures and
recording of EGFP fluorescence of live cultures at the specified points of time (b
and c 1 day; d and e 2 days; f and g 3 days; h and j 5 days; k and l
7 days; m and n 25 days after transduction). (b, d, f, h, k, m) Transduction with
AAV-8a2 (mCMV-EGFP); (c, e, g, j, l, n) transduction with AAV-6p1 (hSYN-
EGFP). (o) the genome sizes occupied by different currently used transcriptional
control elements are shown. The scale denotes the cloning capacity of AAV-2
based vectors (4.7 kb). The stippled line between promoters and 3-regulatory
elements points up the residual capacity for transgenes to be inserted into the
vector. Ellipsoids denote introns, pentagons denote the WPRE, and rectangles
denote polyadenylation sites.
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Fig. 2. Transduction properties of AAV-2 vectors with hSYN and mCMV promoters in cultures of primary brain cells. Transductions with AAV-6p1
(expression cassette: hSYN-Bcl-XL and hSYN-EGFP) and AAV-8a2 (expression cassette: hSYN-Bcl-XL and mCMV-EGFP) were performed in cocultures
of hippocampal neurons and glial cells that were prepared from embryonic brains (E18) and seeded on coverslips. Cultures were transduced at day in vitro
5 with a multiplicity of infection of 1000 and were fixed and stained with the respective antibodies at 10 days after transduction. The left column of the figure
(a, d, g, k, and n) shows the EGFP fluorescence obtained from either the hSYN (AAV-6p1) or the mCMV (AAV-8a2) promoter. The center column (b, e,
h, l, and o) shows immunoreactivity for the neuronal antigen NeuN (b and e), the astrocyte antigen GFAP (h), and the epitope tag FLAG (l and o; incorporated
in the Bcl-XL transgene, which both vectors express under control of the hSYN promoter). A Cy3-labeled secondary antibody was used for visualization.
The right column (c, f, j, m, and p) shows double exposures for EGFP and the respective immunoreactivity. Arrows in (d–f) point to a subset of neurons which
show EGFP expression after AAV-8a2 (mCMV-EGFP) transduction. (k–m) Arrows point to neurons which express EGFP but not FLAG tagged Bcl-XL.
Fig. 3. Transduction properties of AAV-2 vectors with hSYN and mCMV promoters in the adult rat retina and brain. Transductions with AAV-6p1
(expression cassette: hSYN-Bcl-XL and hSYN-EGFP) and AAV-8a2 (expression cassette: hSYN-Bcl-XL and mCMV-EGFP) were performed in the retina
(a–f) or brain (g–r) of adult rats. (a) Retinal ganglion cells retrogradely labeled with the fluorescent tracer FluoroGold. Abbreviations: GCL, ganglion cell
layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; PRL, photo receptor layer; PE, pigment
epithelium). (b) EGFP expression from the hSYN promoter after intravitreal transduction with AAV-6p1. (c) Double exposure of FluoroGold and EGFP
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To our knowledge, the murine CMV promoter has not
been used in AAV vectors before. We tested this short
promoter, because it has been shown that the murine CMV
promoter permits for even stronger transgene expression
with less species restriction than the commonly used human
CMV promoter (Addison et al., 1997). Since AAV vectors
are “slow” with respect to the onset of transgene expression
due to the time it needs to convert the single-stranded vector
genome into transcribeable double-stranded DNA, we ex-
pected that a very strong promoter might be useful to
achieve faster transgene expression. The neuronal tropism
of AAV-2 vectors should thereby target expression to neu-
rons. However, we found that only in the thalamus the
mCMV promoter showed activity comparable to the hSYN
promoter. In cortical and retinal neurons there was weak, if
any, transgene expression from the mCMV promoter but
some strong glial expression instead. Strikingly, in cultured
brain cells obtained from embryonic hippocampus, the
mCMV promoter targeted AAV-2 vectors mainly to astro-
cytes. There appears to be a pronounced difference in the
tropism of AAV-2 vectors in either adult brain or embryonic
brain cell culture. Although the human and the murine
cytomegaloviruses have an identical tropism, the sequences
of their immediate-early promoters show drastic differences
for known consensus binding sites of cellular transcription
factors (Sandford and Burns, 1996). Therefore, these two
promoters may have very different expression kinetics de-
pending on the transduced tissue. After all, the results ob-
tained with the hSYN and the mCMV promoter stress the
fact that cellular promoters are superior to viral promoters
and further suggest that the short human synapsin 1 gene
promoter fragment might be valuable in gene therapy ap-
proaches in primates and even humans. The high affinity of
AAV-2 based vectors for nigral dopaminergic neurons
(Bjo¨rklund et al., 2000) favors the use of the described
vector system in Parkinson’s research, making it possible to
express either large transgenes or a combination of two
transgenes. Monitoring of both spatial and temporal trans-
duction efficacy is critical in models of inhibition of neu-
rological degeneration as well as in attempts to generate
genetic models of idiopathic Parkinson’s syndrome by
means of viral vector-mediated gene expression. The coex-
pression of a versatile reporter gene (like EGFP or DsRed)
together with the transgene under investigation may there-
fore greatly facilitate quantitative studies. In case of space
restrictions of vector genomes internal ribosomal entry sites
may be helpful in order to express a combination of trans-
genes. However, small promoters and polyadenylation sites
allowing the expression of two transgenes under control of
identical transcriptional control elements should be favor-
able simply because both transgenes will be expressed in-
dependently but with identical kinetics. As mentioned
above, this strategy will also be valuable for neurotraumatic
research in the retino-tectal projection (axotomy of retinal
ganglion cell axons), which serves as an broadly accepted
model for traumatic neuronal injury (Ba¨hr, 2000).
Materials and methods
Bicistronic expression cassettes (Bcl-XL under hSYN
promoter control and EGFP under either hSYN promoter or
mCMV immediate-early promoter control, Fig. 1a) were
cloned into pTR-UF 22, from which all elements in between
the ITRs except the WPRE and the bGH polyadenylation
site were removed. Recombinant vector was prepared by the
University of Florida vector core, using an adenovirus-free
protocol (Zolothukin et al., 1999). A genome titer as deter-
mined by dot blot were 5.9 1012/ml for AAV-8a2 and 4.3
 1012/ml for AAV-6p1. A transducing titer of AAV-8a2
(which contained EGFP under mCMV promoter control)
was determined by co-infection with adenovirus on 293
cells and was 6  1010 transducing units/ml. Matching
transducing titer for AAV-6p1 was determined on cultured
hippocampal neurons by staining cells with an anti-FLAG
antibody (M2, Stratagene) for the epitope-tagged Bcl-XL,
which in both vectors was expressed under hSYN promoter
control. For expression experiments on cultured neurons,
vectors were used at a theoretical m.o.i. of 1000 transducing
units per cell. Preparation of primary neuronal cultures has
been described (de Hoop et al., 1998; Ku¨gler et al., 2001).
Retrograde labeling of retinal ganglion cells was performed
by stereotaxic injection of the tracer FluoroGold into the
superior colliculi 7 days before vector application. Vectors
were injected into the temporal retinal side intraocularly by
means of a fine glass capillary attached via tubing to a
Hamilton syringe (1  1010 genomes). Stereotaxic vector
applications into the brain (1–2  109 genomes) were per-
formed according to the coordinates of Paxinos and Watson
(1998) into primary motor cortex (B: 1.7, L: 3, DV: 2),
fluorescence; arrows point to few cells which are expressing EGFP but are not retinal ganglion cells. (d) Double exposure of EGFP fluorescence (green) and
Bcl-XL immunoreactivity (red) after intravitreal AAV-6p1 transduction, yellow color denotes coexpression of both transgenes. (e) Double exposure of EGFP
fluorescence (green) and Bcl-XL immunoreactivity (red) after intravitreal AAV-8a2 transduction (arrowheads point to retinal ganglion cells expressing Bcl-XL
from the hSYN promoter, the arrow denotes a Mu¨ller glia cell expressing EGFP from the mCMV promoter. (f) Retinal section after mock transduction and
Bcl-XL antibody staining. (g) EGFP expression in striatum after AAV-6pl (hSYN-EGFP) transduction. (h) Identical section as in (g) stained for the neuron
specific antigen NeuN. (j) Triple exposure of EGFP fluorescence (green), NeuN immunoreactivity (red), and nuclear DAPI stain (blue) (k) Strong EGFP
expression in cortical neurons after AAV-6p1 (hSYN-EGFP) transduction. (l) Weak EGFP expression in cortical neurons after AAV-8a2 (mCMV-EGFP)
transduction; arrows point to some glial cells (as identified by colocalization with the astrocyte marker GFAP; not shown) that strongly express EGFP. (m
and n) equally strong EGFP expression in thalamic neurons driven by either the hSYN or the mCMV promoter. (o–r) Striatal transduction with AAV-6p1
showing expression of both transgenes, EGFP (o and q) and Bcl-XL the latter detected by either the FLAG epitope antibody (p) or the Bcl-X antibody (r).
Arrows point to striatal neurons which show EGFP expression but not Bcl-XL expression.
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striatum (B: 0.2, L: 3, DV: 5.7), and thalamus/globus pal-
lidus (B: 0.8, L: 2, DV: 7). A 2-l viral suspension was
injected over 5 min into female Wistar rats (260 g body wt)
anesthesized with chloralhydrate (420 mg/kg). Brains were
perfused at 5 weeks after transduction; cut to 16-m sec-
tions; and stained with anti-NeuN (Chemicon), anti-FLAG
(Stratagene), and anti-Bcl-X (Transduction Laboratories).
Cy3-labeled secondary antibody was used for visualisation
on a Zeiss Axiovert Microscope equipped with a CCD
camera.
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